Regulation of Glut1 MRNA by Hypoxia-inducible Factor-1. Interaction Between H-ras and Hypoxia
Overview
Authors
Affiliations
Oncogenic transformation and hypoxia both induce glut1 mRNA. We studied the interaction between the ras oncogene and hypoxia in up-regulating glut1 mRNA levels using Rat1 fibroblasts transformed with H-ras (Rat1-ras). Transformation with H-ras led to a substantial increase in glut1 mRNA levels under normoxic conditions and additively increased glut1 mRNA levels in concert with hypoxia. Using a luciferase reporter construct containing 6 kilobase pairs of the glut1 promoter, we showed that this effect was mediated at the transcriptional level. Promoter activity was much higher in Rat1-ras cells than in Rat1 cells and could be down-regulated by cotransfection with a dominant negative Ras construct (RasN17). A 480-base pair (bp) cobalt/hypoxia-responsive fragment of the promoter containing a HIF-1 binding site showed significantly higher activity in Rat1-ras cells than in Rat1 cells, suggesting that Ras might mediate its effect through HIF-1 even under normoxic conditions. Consistent with this, Rat1-ras cells displayed higher levels of HIF1-alpha protein under normoxic conditions. In addition, a promoter construct containing a 4-bp mutation in the HIF1 binding site showed lower activity in Rat1-ras cells than a construct with an intact HIF1 binding site. The activity of the latter construct but not the former could be down-regulated by RasN17, supporting the importance of the HIF1 binding site in regulation by Ras. The phosphatidylinositol 3-kinase inhibitor LY29004 down-regulated glut1 promoter activity and mRNA levels under normoxia and also decreased HIF1alpha protein levels in these cells. Collectively these results indicate that H-Ras up-regulates the glut1 promoter, at least in part, by increasing HIF-1alpha protein levels leading to transactivation of promoter through the HIF-1 binding site.
McCaffrey E, Delmastro A, Fitzhugh I, Ranek J, Douglas S, Peters J bioRxiv. 2025; .
PMID: 40027668 PMC: 11870603. DOI: 10.1101/2025.02.18.638923.
Berto Gomes L, Smith O, Bollwein H, Kowalewski M Animals (Basel). 2025; 15(4).
PMID: 40003076 PMC: 11851762. DOI: 10.3390/ani15040595.
Therapeutic Effects of Taurine and Histidine Supplementation in Retinal Diseases.
Lee D, Smith L Life (Basel). 2025; 14(12.
PMID: 39768274 PMC: 11676320. DOI: 10.3390/life14121566.
Trentini F, Agnetti V, Manini M, Giovannetti E, Garajova I Front Pharmacol. 2024; 15:1499414.
PMID: 39723256 PMC: 11668609. DOI: 10.3389/fphar.2024.1499414.
Zhu Z, Sun J, Xu W, Zeng Q, Feng H, Zang L Adv Sci (Weinh). 2024; 11(48):e2409764.
PMID: 39527463 PMC: 11672308. DOI: 10.1002/advs.202409764.